Respiratory Medicine
Volume 104, Issue 2 , Pages 211-218 , February 2010

Effects of corticosteroid use on readmission in obstructive lung disease

  • Karin J. Velthove

      Affiliations

    • Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, The Netherlands
    • Department of Clinical Chemistry and Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands
    • ,
  • Patrick C. Souverein

      Affiliations

    • Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, The Netherlands
    • ,
  • Wouter W. van Solinge

      Affiliations

    • Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, The Netherlands
    • Department of Clinical Chemistry and Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands
    • ,
  • Hubert G.M. Leufkens

      Affiliations

    • Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, The Netherlands
    • ,
  • Jan-Willem J. Lammers

      Affiliations

    • Department of Respiratory Medicine, Division of Heart and Lungs, University Medical Center Utrecht, Internal Post No. E 03.511, PO Box 85500, 3508 GA Utrecht, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 88 755 6180; fax: +31 88 755 5415.

Received 2 June 2009 ,Accepted 28 August 2009.

References 

  1. From the global strategy for the diagnosis management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from: http://www.goldcopd.org2008;
  2. From the global strategy for asthma management and prevention. Global Initiative for Asthma (GINA). Available from: http://www.ginasthma.org2008;
  3. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523–532
  4. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29:906–913
  5. Tattersfield A, Knox A, Britton J, Hall I. Asthma. Lancet. 2002;360:1313–1322
  6. Robinson D, Campbell D, Durham S, Pfeffer J, Barnes P, Chung K. Systematic assessment of difficult-to-treat asthma. Eur Respir J. 2003;22:478–483
  7. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009;179:19–24
  8. Vermeire P, Rabe K, Soriano J, Maier W. Asthma control and differences in management practices across seven European countries. Respir Med. 2002;96:142–149
  9. Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy. 2007;62:126–133
  10. McKnight J, Scott A, Menzies D, Bourbeau J, Blais L, Lemière C. A cohort study showed that health insurance databases were accurate to distinguish chronic obstructive pulmonary disease from asthma and classify disease severity. J Clin Epidemiol. 2005;58:206–208
  11. Miller MK, Lee JH, Blanc PD, et al. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J. 2006;28:1145–1155
  12. Ekberg-Aronsson M, Lofdahl K, Nilsson JA, Lofdahl CG, Nilsson PM. Hospital admission rates among men and women with symptoms of chronic bronchitis and airflow limitation corresponding to the GOLD stages of chronic obstructive pulmonary disease – a population-based study. Respir Med. 2008;102:109–120
  13. Blais L, Ernst P, Boivin JF, Suissa S. Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med. 1998;158:126–132
  14. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;21:795–798
  15. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health. 1992;46:136–140
  16. Kiri VA, Bettoncelli G, Testi R, Viegi G. Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA. Respir Med. 2005;99:1115–1124
  17. Roede BM, Bresser P, Bindels PJ, et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax. 2008;63:968–973
  18. Blais L, Suissa S, Boivin JF, Ernst P. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. Thorax. 1998;53:1025–1029
  19. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57:880–884
  20. Rice KL, Rubins JB, Lebahn F, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am J Respir Crit Care Med. 2000;162:174–178
  21. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. Asthma exacerbations during first therapy with long acting beta 2-agonists. Pharm World Sci. 1999;21:116–119
  22. Breekveldt-Postma NS, Erkens JA, Aalbers R, van de Ven MJ, Lammers JW, Herings RM. Extent of uncontrolled disease and associated medical costs in severe asthma – a PHARMO study. Curr Med Res Opin. 2008;24:975–983
  23. Van Ganse E, Van der Linden PD, Leufkens HG, Herings RM, Vincken W, Ernst P. Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance. Eur Respir J. 1995;8:1856–1860
  24. Breekveldt-Postma NS, Gerrits CM, Lammers JW, Raaijmakers JA, Herings RM. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med. 2004;98:752–759
  25. Ten Brinke A, Sterk P, Masclee A, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J. 2005;26:812–818
  26. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197–203
  27. Malfertheiner P, Hallerback B. Clinical manifestations and complications of gastroesophageal reflux disease (GERD). Int J Clin Pract. 2005;59:346–355
  28. Menckeberg TT, Belitser SV, Bouvy ML, et al. Distinguishing patterns in the dynamics of long-term medication use by Markov analysis: beyond persistence. BMC Health Serv Res. 2007;7:106
  29. Krishnan JA, Riekert KA, McCoy JV, et al. Corticosteroid use after hospital discharge among high-risk adults with asthma. Am J Respir Crit Care Med. 2004;170:1281–1285
  30. Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009;150:178–187
  31. Almagro P, Barreiro B, Ochoa de Echaguen A, et al. Risk factors for hospital readmission in patients with chronic obstructive pulmonary disease. Respiration. 2006;73:311–317
  32. Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J. 2005;26:414–419
  33. Frey U, Suki B. Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet. 2008;372:1088–1099
  34. Watson L, Vonk JM, Lofdahl CG, et al. Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. Respir Med. 2006;100:746–753
  35. Pauwels RA. Similarities and differences in asthma and chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc. 2004;1:73–76
  36. Breekveldt-Postma NS, Koerselman J, Erkens JA, van der Molen T, Lammers JW, Herings RM. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol Drug Saf. 2008;17:411–422
  37. Suissa S, McGhan R, Niewoehner D, Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4:535–542
  38. Kiri VA, Pride NB, Soriano JB, Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med. 2005;172:460–464
  39. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 1998;351:773–780
  40. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–1303
  41. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789
  42. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?. Eur Respir J. 2003;21:260–266
  43. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:580–584
  44. De Vries F, Pouwels S, Bracke M, et al. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case–control study. Pharmacoepidemiol Drug Saf. 2007;16:612–619
  45. Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol. 1996;144:1161–1169
  46. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 2002;20:819–825

PII: S0954-6111(09)00285-6

doi: 10.1016/j.rmed.2009.08.014

Respiratory Medicine
Volume 104, Issue 2 , Pages 211-218 , February 2010

Article Tools

* Image Usage & Resolution